Compare Logitech International SA (LOGI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Logitech (LOGI) trades at $98.27, down 3.83% over the past day, amid a neutral technical backdrop. The stock shows strong fundamental health with consistent earnings beats, a robust net income margin of 16.28%, and a forward P/E of 18.64. Recent product launches, including the Zone Vibe Pro headset and MX Keypad, highlight innovation in the hybrid work and gaming segments. Cash flow trends are positive, with 2026 operating cash flow projected at $1.1 billion, supporting dividend payments and growth initiatives.

The investment outlook is balanced. Upside is supported by solid profitability, strategic partnerships like the SEGA alliance, and analyst consensus target of $107. However, risks include competitive pressures in peripherals, sensitivity to consumer spending, and the stock's high P/B ratio of 6.18. Investor sentiment is mixed, with technical indicators neutral and analyst ratings evenly split between buy, hold, and sell.

Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.

The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.